NCT00330551View on ClinicalTrials.gov

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Schizophrenia
Interventions
DRUG

Oral Risperidone

Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.

DRUG

Risperidone in Long-Acting Injectable Form (Consta)

Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.

Trial Locations (1)

90095

Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

University of California, Los Angeles

OTHER

NCT00330551 - Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia | Biotech Hunter | Biotech Hunter